Effects of Acetaminophen Exposure on Outcomes of Patients Receiving Immune Checkpoint Inhibitors for Advanced Non-Small-Cell Lung Cancer: A Propensity Score-Matched Analysis

被引:3
作者
Nelli, Fabrizio [1 ]
Virtuoso, Antonella [1 ]
Giannarelli, Diana [2 ]
Fabbri, Agnese [3 ]
Berrios, Julio Rodrigo Giron [3 ]
Marrucci, Eleonora [3 ]
Fiore, Cristina [3 ]
Ruggeri, Enzo Maria [3 ]
机构
[1] Cent Hosp Belcolle, Dept Oncol & Hematol, Thorac Oncol Unit, I-01100 Viterbo, Italy
[2] Fdn Policlin Univ A Gemelli, Ist Ricovero & Cura Carattere Sci IRCCS, Biostat Unit, Sci Directorate, I-00168 Rome, Italy
[3] Cent Hosp Belcolle, Dept Oncol & Hematol, Med Oncol Unit, I-01100 Viterbo, Italy
关键词
non-small-cell lung cancer; immune checkpoint inhibitors; first-line therapy; second-line therapy; acetaminophen; disease control benefit; survival; NONSMALL; ASSOCIATION; RESPONSES; SURVIVAL; EFFICACY; CRITERIA; RECIST;
D O I
10.3390/curroncol30090589
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
(1) Background: Several studies have investigated potential interactions between immune checkpoint inhibitors (ICIs) and commonly prescribed medications. Although acetaminophen (APAP) has not been considered susceptible to interaction with ICIs, recent research has shown that detectable plasma levels of this drug can hinder the efficacy of PD-1/PD-L1 blockade therapies. A reliable assessment of the potential interaction between APAP and ICIs in advanced non-small cell lung cancer (NSCLC) patients would be worthwhile since it is often prescribed in this condition. We sought to evaluate the impact of the concomitant use of APAP in patients with advanced NSCLC on PD-1/PD-L1 blockade using real-world evidence. (2) Methods: This study included consecutive patients with histologically proven stage IV NSCLC who underwent first-line therapy with pembrolizumab as a single agent or in combination with platinum-based chemotherapy, or second-line therapy with pembrolizumab, nivolumab, or atezolizumab. The intensity of APAP exposure was classified as low (therapeutic intake lasting less than 24 h or a cumulative intake lower than 60 doses of 1000 mg) or high (therapeutic intake lasting more than 24 h or a total intake exceeding 60 doses of 1000 mg). The favorable outcome of anti-PD-1/PD-L1 therapies was defined by durable clinical benefit (DCB). Progression-free survival (PFS) and overall survival (OS) were relevant to our efficacy analysis. Propensity score matching (PSM) methods were applied to adjust for differences between the APAP exposure subgroups. (3) Results: Over the course of April 2018 to October 2022, 80 patients were treated with first-line pembrolizumab either as single-agent therapy or in combination with platinum-based chemotherapy. During the period from June 2015 to November 2022, 145 patients were given anti-PD-1/PD-L1 blockade therapy as second-line treatment. Subsequent efficacy analyses relied on adjusted PSM populations in both treatment settings. Multivariate testing revealed that only the level of APAP and corticosteroid intake had an independent effect on DCB in both treatment lines. Multivariate Cox regression analysis confirmed high exposure to APAP and immunosuppressive corticosteroid therapy as independent predictors of shorter PFS and OS in both treatment settings. (4) Conclusions: Our findings would strengthen the available evidence that concomitant intake of APAP blunts the efficacy of ICIs in patients with advanced NSCLC. The detrimental effects appear to depend on the cumulative dose and duration of exposure to APAP. The inherent shortcomings of the current research warrant confirmation in larger independent series.
引用
收藏
页码:8117 / 8133
页数:17
相关论文
共 50 条
  • [21] Metabolomics to Assess Response to Immune Checkpoint Inhibitors in Patients with Non-Small-Cell Lung Cancer
    Ghini, Veronica
    Laera, Letizia
    Fantechi, Beatrice
    del Monte, Francesca
    Benelli, Matteo
    McCartney, Amelia
    Leonardo, Tenori
    Luchinat, Claudio
    Pozzessere, Daniele
    CANCERS, 2020, 12 (12) : 1 - 16
  • [22] Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer
    Yamagata, Akira
    Yokoyama, Toshihide
    Fukuda, Yasushi
    Ishida, Tadashi
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (02) : 251 - 258
  • [23] Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
    Li, Xing
    Wang, Lei
    Chen, Shanhao
    Zhou, Fei
    Zhao, Jing
    Zhao, Wencheng
    Su, Chunxia
    THORACIC CANCER, 2020, 11 (10) : 2812 - 2819
  • [24] Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non-small-cell lung cancer
    Morita, Ayako
    Ichihara, Eiki
    Inoue, Koji
    Fujiwara, Keiichi
    Yokoyama, Toshihide
    Harada, Daijiro
    Ando, Chihiro
    Kano, Hirohisa
    Oda, Naohiro
    Tamura, Tomoki
    Ochi, Nobuaki
    Kawai, Haruyuki
    Inoue, Masaaki
    Hara, Naofumi
    Fujimoto, Nobukazu
    Ichikawa, Hirohisa
    Oze, Isao
    Hotta, Katsuyuki
    Maeda, Yoshinobu
    Kiura, Katsuyuki
    INTERNATIONAL JOURNAL OF CANCER, 2024, 154 (09) : 1607 - 1615
  • [25] Adjuvant chemotherapy may improve long-term outcomes in stage IB non-small cell lung cancer patients with previous malignancies: A propensity score-matched analysis
    Zhou, Ke
    Zhao, Yaqin
    Liang, Linchuan
    Cao, Jie
    Lin, Huahang
    Peng, Zhiyu
    Mei, Jiandong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [26] Lower tumor volume is associated with increased benefit from immune checkpoint inhibitors in patients with advanced non-small-cell lung cancer
    Icht, Oded
    Domachevsky, Liran
    Groshar, David
    Dudnik, Elizabeth
    Rotem, Ofer
    Allen, Aaron M.
    Peled, Nir
    Reinhorn, Daniel
    Jacobi, Oded
    Shochat, Tzippy
    Bernstine, Hanna
    Zer, Alona
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 (02) : E125 - E131
  • [27] Immune checkpoint inhibitors for first-line treatment of advanced non-small-cell lung cancer: A systematic review and network meta-analysis
    Peng, Tzu-Rong
    Lin, Hung-Hong
    Tsai, Fang-Pei
    Wu, Ta-Wei
    THORACIC CANCER, 2021, 12 (21) : 2873 - 2885
  • [28] The Levels of Interferon-gamma Release as a Biomarker for Non-small-cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors
    Hirashima, Tomonori
    Kanai, Tomohiro
    Suzuki, Hidekazu
    Yoshida, Hiroko
    Matsushita, Akane
    Kawasumi, Hiromi
    Samejima, Yumiko
    Noda, Yoshimi
    Nasu, Shingo
    Tanaka, Ayako
    Morishita, Naoko
    Hashimoto, Shoji
    Kawahara, Kunimitsu
    Tamura, Yoshitaka
    Okamoto, Norio
    Tanaka, Toshio
    ANTICANCER RESEARCH, 2019, 39 (11) : 6231 - 6240
  • [29] The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors
    Takada, Kazuki
    Shimokawa, Mototsugu
    Takamori, Shinkichi
    Shimamatsu, Shinichiro
    Hirai, Fumihiko
    Ono, Yuki
    Tagawa, Tetsuzo
    Okamoto, Tatsuro
    Hamatake, Motoharu
    Okamoto, Isamu
    Mori, Masaki
    PLOS ONE, 2022, 17 (02):
  • [30] The efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer with liver metastases
    Kitadai, Rui
    Okuma, Yusuke
    Hakozaki, Taiki
    Hosomi, Yukio
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2020, 146 (03) : 777 - 785